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A 1,Cdihydroypyridine arylazide photoaffinity ligand, [3H]azidopine (SO.6 Ci/mmol), has been 
synthesized. [‘H]Azidopine binds reversibly with a Kd of 350 pM to guinea-pig skeletal muscle membranes 
in the absence of ultraviolet light. The reversible [3H]azidopine binding is inhibited stereoselectively by 
1,4_dihydropyridines, phenylalkylamine Ca’+ channel blockers and La3+. Covalent incorporation into 
membrane proteins after photolysis was investigated by sodium dodecyl sulfate polyacrylamide slab gel 
electrophoresis. [3H]Azidopine is photoincorporated specifically into a protein of M, -145000. The 
covalent labelling of the h4, - 145 000 band is inhibited stereoselectively by drugs and cations which block 
the reversible [3H]azidopine binding. It is suggested that [3H]azidopine is photoincorporated into a subunit 
of the putative Ca*+ channel. 
Calcium channel Photoaffinity label Skeletal muscle f ‘H]Azidopine 1,4_Dihydropyridine 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Ca2+ channels in the skeletal muscle t-tubulus 
are blocked by 1 ,Cdihydropyridines (e.g., 
nifedipine), phenylalkylamines (e.g., D-600) and 
divalent cations (e.g., Ni2+) [l]. These Ca2+ chan- 
nels can be identified in broken cell preparations 
by radiolabelled 1 ,Cdihydropyridines [2,3]. Target 
size analysis has revealed that the 1 ,Cdihydropyri- 
dine binding sites, associated with the skeletal mus- 
cle t-tubulus Ca2+ channels, are large structures of 
Mr 136000-210000 [4-61. An oligomeric structure 
of the channel has been proposed from results with 
different 1 ,Cdihydropyridines and the effects of d- 
cis-diltiazem (an allosteric regulator) in modulat- 
ing apparent channel size [4,6]. We report here the 
synthesis and properties of a novel l,Cdihydro- 
pyridine arylazide ligand ([3H]azidopine) which is 
photoincorporated specifically into skeletal muscle 
membrane proteins. 
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2.1. Materials 
Sources of materials were as in [2,4,6,7]. Partial- 
ly purified skeletal muscle t-tubule membranes 
from guinea-pig were prepared as in [2]. 
2.2. Preparation of rH]azidopine 
All procedures were performed in close to total 
darkness. One mCi succinimidyl-4-azidobenzoate 
(50.6 Ci/mmol, NEN, Dreieich) was evaporated to 
dryness under a gentle stream of nitrogen. Two 
hundred nmol 1,4-dihydro-2,6-dimethyl-4-(2-tri- 
fluoromethylphenyl)-3,5pyridine carboxylic acid 
2-(aminoethyl) ethyl ester in 20 ~1 absolute ethanol 
were added followed by 20 ~1 of 100 mM sodium 
borate buffer (pH 8.4). After 25 min on ice the 
reaction mixture was spotted on a 0.2 mm silica gel 
60 thin-layer plate (Merck A.G., Darmstadt) and 
[3H]azidopine purified by ascending chromato- 
graphy (solvent system: acetic acid ethyl ester- 
diethyl ether, 30 : 70, v/v). [3H]Azidopine had an 
Rf value of 0.54. The azidopine precursor remain- 
ed on the origin and non-reacted succinimidyl4- 
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~idob~~z~~t~ had an Rf value of -0.80. [“H]Azi- 
dopine was eiuted with absofute thanol and stored 
for up to 6 weeks at - 20% with no radiochemicaf 
decay of the hgand. The reaction yield of 
[3H]azidopine was -30% of the starting radio- 
activity, the radiochemical purity 395%. 
Characteristics of reversibb f3Hfazidopine bind- 
ing (in total darkness) were evatuated in 50 mM 
B-is-NC1 buffer, supplemented with 0.1 mM 
phenylm~t~ylsulfony~ fluoride (PMSF) (pH 7.4) 
(buffer A) in an assay volume of 0.25 ml at 25°C. 
Bound and free ligand were separated as in [3]. 
The nonspecific binding de~~i~on was with 1 FM 
n~mod~pin~~ the incubation time being 1 h unless 
stated otherwise. f3H]Azidopine isracemic and the 
binding abihty of the ligand is -50% as reported 
in f2] for other racemic ~,4~~~H]dihydropy~i~i~~s. 
This was taken into account for the data cafcula- 
tion, except when stated otherwise. 
Guinea-pan skeletal muscle membranes (protein 
1-2 mg/ml) in buffer A were incubated with 
2.5 nM ~3HJ~idopine (total binding), or 2,5 nM 
f3Hfazidopine in the presence of 100 aM f+)- 
enantiomer of PN 200-I O (blank binding) or other 
drugs in a volume of 4 ml, After 60 min incuba- 
tion at 2S°C the assay rn~t~~e was centrifuged at 
35000 x g for 10 min at 2*C, The first supwnatant 
was discarded and the peltets resuspended in 4 ml 
ice-&d buffer A, suppiemented with 0.25 mg/ml 
bovine serum albumin (fat free; Sigma, Munich), 
The centrif~~ation was repeated, the supernatant 
discarded and the pellets ~~~~spended in 4 ml ice- 
cold buffer A. The suspensions were irradiated 
with a Philips TL 40 W/08 bla~k~~ight tamp in an 
8 cm diameter petri dish at a distance of 10 cm for 
3 min on ice, The irradiated suspensions were spun 
down as above and the pellets resuspended in 50 $1 
buffer A. Twenty al of a protease inhibitor mixture 
(containing 0.14 mg/ml leupeptin, 0.7 mM ben- 
zamidine, 0.7 mM PMSF, 2.8 mM EDTA, 
0,02 n-&ml Trasyfole and 0.14 mgi’ml pepstatin 
A) was added, After 20 mm, 0,2 mf of boiling stop 
solution was added to each tube, The corn~~~jtion 
of the stop solution was 25 ml of 20% SDS, 
0.5 ml ,&mercaptoethanol, f .O ml glycerol, 1 ,O mf 
of 0.625 M Tris-HCI, 0.1 mM PMSF (pH 7.5), 
with 1.8 g urea added to the mixture and brom- 
phenol blue. After 10 min at 25OC the denatured 
membranes were applied to 11% homogeneous 
slab gels as in f7J. “‘C-labelled marker proteins 
were from NEN (Dreieich). Following eiee- 
trophoresis the slab gels were either cut and 
counted for radioactivity or prepafed for fluoro- 
graphy and dried, Gels which were counted for 
radioactivity were not fixed and cut into 3 mm 
slices, The slices were so~ubi~i~ed for 3 days in 
3.5 ml of liquid scintiliation cocktail. (Lipoioma 
zmd Liposolve, Baker Chemicals, Deventer, The 
Netherlands). Gels for fluorography were first fix- 
ed for 30 min then impregnated with Enhghtening 
(NEN) for 1 h. Gels were dried and then exposed 
to Kodak XC&mat film for 14 days at - 70°C. 
Binding inhibition data were fitted by non-linear 
methods to the general dose-response equation [8f 
and the .Ki values determined as in [9] m Means were 
compared with Student’s t-test, p $0.05 being the 
level of accepted significance. 
3, RESULTS 
[3H]Azidopine bound with a & af 350 f 50 pM 
(25°C) to guinea-pan skeletal muscle membranes. 
The &= was 28 f 4 pmol (n = 3) per mg mem- 
brane protein. The association rate constant, &+I 
w&s 0,378 nM_’ bmin-‘, and the association rate 
constant, k-r, was 0,15 mm” as determined by 
computer fitting of the association data. However, 
k-1, when determined by blockade of the associa- 
tion reaction with unlabeIled nimodipine (1 pM& 
was 0,016 min- ’ (fig.1). This discrepancy is cur- 
rently under investigation. ~~abeIled f ,4dihydro- 
pyridines displaced [3H&zzidopine binding in a 
stereoselective manner, the ( + )-enantiomer of PN 
200-l 10 being more potent than the (-)-enanti- 
omer (fig.2). Phenylalkylamines were partially in- 
hibitory under the assay conditions employed. 
( f )-Verapamil displaced 51% of specific 13H]- 
azidopine binding whereas ( - )-verapamii displac- 
ed only 24%. (- )-Verapamil is, however, more 
patent than ( f )-verapamil. When ( -t )-verapamil 
at tOaM together with 1 pM nimodipine was used 
to block the association reaction, the dissociation 
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Fig.1. Kinetics and saturability of [3H]azidopine 
binding. (A) Association reaction of [3H]azidopine to 
guinea-pig skeletal muscle membranes. [3H]Azidopine 
(339 PM) was incubated with 6.6pg membrane protein 
for times between 1 and 50 min at 25°C. Blank binding 
was 22 pM, instantaneous, stable and was subtracted 
from the data points. (B) Dissociation of [‘Hlazidopine. 
Br is the specifically bound ligand at time t after addition 
of chasing drugs and Be the equilibrium specific binding. 
Dissociation was induced by 1 PM nimodipine (u) 
resulting in a k+r of 0.016 k 0.01 min-’ (n = 3) or by 
1 PM nimodipine together with 10 pM (+ )-verapamil 
(0). The k-r was 0.034 min-‘. (C) Saturation isotherm 
of [3H]azidopine binding. [3H]Azidopine (free 
concentration 13-1780 PM) was incubated with 5.4,~g 
membrane protein. Specific binding (A) and nonspecific 
binding (A) are shown. Computerized data fitting gave 
a B,,, of 543 f 50 pM (B,a, 25 + 2.3 pmol/mg protein) 
MOO and a Kd of 342 f 40 pM. 
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Fig.2. Pharmacological profile of [3H]azidopine. [‘H]Azidopine (0.4-0.6 nM) was incubated with lo-12 gg skeletal 
muscle membrane protein. The total bound radioactivity was 1000@-12000 dpm and blank binding 5-600 dpm. Data 
were fitted with the BMDP genera1 curve fitting program to the dose-response quation [8]. Values are given f 
asymptotic SD, (A) Stereoselective inhibition of [‘Hlazidopine binding by the (+)-enantiomer (m) and ( - )-enantiomer 
(0) of PN 200-l 10. Each point is the mean of a duplicate determination, data points having been pooled from 3 
independent experiments. For (+)-PN 200-110 an ZCSO of 3.6 f 0.5 nM and a slope factor of 1.4 f 0.15 gave the best 
fit. The Ki of (+)-PN 200-l 10 was 0.3 nM. For (-)-PN 200-l 10 the IGO was 1800 + 970 nM and the slope factor 0.76 * 
0.17. The Ki of (-)-PN 200-110 is 343 nM. (B) Stereoselective inhibition of specific [3H]azidopine binding by (+)- 
verapamil (A) and (-)-verapamil (A). Data points are means of duplicate determinations from 3 independent 
experiments f SE. For (+)-verapamil the ZC5o was 350 f 100 nM, slope factor 0.74 f 0.15 and the maximal inhibition 
51 f 4% of specific binding. For (-)-verapamil the I& was 44 ? 36 nM, the slope factor 0.62 + 0.35 and maximal 
114 
inhibition 24 f 3%. * p < 0.01 for (+ )-verapamil vs (- )-verapamil. 
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was accelerated 2-fold (k = 0.034 min-‘). This 
demonstrates the negative allosteric nature of 
phenylalkylamine inhibition of [3H]azidopine bin- 
ding. As previously reported for [3H]PN 200-110 
binding [6] d-cis-diltiazem caused a very small 
stimulation of [3H]azidopine binding (not shown). 
In addition, [3H]azidopine binding was inhibited 
by the inorganic Ca2+ channel blocker La3+ with 
an I& of 100 PM whereas Ca2+ up to 10 mM and 
Na+ (all as chloride salts) up to 100 mM were com- 
pletely inactive. 
3.2. Photoaffinity labeling with 13HJazidopine 
The fate of [3H]azidopine in photoaffinity ex- 
periments was monitored. With the above protocol 
(means from 3 balance experiments f SE) 26 * 4% 
of the added racemic [3H]azidopine was specifical- 
ly bound; 27 + 5% of the total [3H]azidopine was 
recovered in the first supernatant and an addi- 
800 0 1000 2000 
DPM /GEL SLICE 
TOTAL 
k 
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tional 34 rt 6% was found in the subsequent 
washing fluids. Following ultraviolet light ex- 
posure, specific binding (assessed by filtration) was 
reduced by -50% and approx., 400000 dpm were 
added to a single lane of the slab gel for elec- 
trophoresis. The efficiency of photoincorporation 
of [3H]azidopine (defined as the ratio of dpm 
found in specific bands in the slab gels relative to 
the equilibrium level of specific binding prior to 
ultraviolet light exposure) was 0.6 f 0.1% (n = 5). 
The small percentage of covalent incorporation is 
common to most arylazide photoaffinity ligands 
(e.g., [lo]) because the nitrene radicals formed can 
react with water [ll]. Preliminary experiments 
without the use of the protease inhibitor mixture 
yielded very little specific covalent incorporation 
of [3H]azidopine in skeletal muscle membranes 
after gel electrophoresis. In guinea-pig heart mem- 
branes only nonspecific photoincorporation into a 
BLANK TOTAL 
Fig.3. Results of a typical photoaffinity experiment. Guinea-pig skeletal muscle membrane protein (1.5 mg/ml) was 
incubated with 2.5 nM [‘Hlazidopine (total binding) or 2.5 nM [3H]azidopine and 100 nM (+)-PN 200-110 (blank 
binding) for 1 h at 25°C. The membranes were then washed, photolyzed, denatured and electrophoresed as described. 
The left side shows the dpm/3 mm gel slice for the blank as well as the corresponding total binding. In gel slices 7 and 
8 of the total binding, 2332 dpm was incorporated specifically. The fluorography of the total and blank binding lanes 
from the same slab gel is shown on the right. Mr standards are shown (non-reduced gamma globulin, 158000; 
phosphorylase b, 92500; bovine serum albumin, 67000; ovalbumin, 46000; fl-lactoglobulin, 18000; all reduced). The 
arrow (*) indicates the position of the specifically labelled band and the apparent M, in these experiments. 
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band of IV, 41000 was seen in the presence of 
PMSF only or even with other protease inhibitors 
present. With the above protocol 2000-4000 dpm 
were consistently incorporated into a band of A4, 
145000 f 5000 (n = 5) in skeletal muscle mem- 
branes. Photoincorporation into this band was 
completely blocked by 100 nM (+)-PN 200-110 
(see fig.3) but not at all by 100 nM (-)-PN 
200-110, and only partially by saturating concen- 
trations of the verapamil enantiomers (not shown). 
This demonstrates that the pharmacological 
specificity of the irreversible t3H]azidopine binding 
is similar to that observed in reversible binding 
studies. 
4. DISCUSSION 
The putative Ca2+ channels from skeletal muscle 
and brain, labelled with tritiated 1 ,Cdihydropyri- 
dines, have been solubilized and partially purified 
with lectin affinity chromatography and sucrose 
gradient centrifugation [ 12,131. In skeletal muscle 
the Ca*+ channel 1 ,Cdihydropyridine binding site 
has an ~20,~ value of -13 S [12]. Target size 
analysis has been employed to estimate the A4, of 
the 1,4-dihydropyridine binding domain. An MI of 
185000 f 10000 [4] was found for the guinea-pig 
skeletal muscle [‘Hlnimodipine labelled site, 
whereas an Mr of 210000 f 20000 was reported for 
the rabbit t-tubule [‘Hlnitrendipine labelled bind- 
ing site [5]. When [3H]PN 200-110 (a 
benzoxadiazol-1 ,Cdihydropyridine) was employed 
as a Ca2+ channel abel, a somewhat smaller Mr of 
136000 f 12000 was found for the skeletal muscle 
1 ,Cdihydropyridine receptor [6]. t3H]PN 200-l 10 
has been classified as a fully ‘antagonistic’ 1,4-di- 
hydropyridine derivative, because of its efficacy in 
stabilizing the high-affinity state of the Ca2+ chan- 
nel 1 ,Cdihydropyridine receptor [ 141. [3H]Nimodi- 
pine and [3H]nitrendipine label considerably less 
high-affinity sites than [3H]PN 200-110 at 37°C 
and have been suggested to be partially agonistic 
1 ,Cdihydropyridines [14]. We have performed 
binding studies with the ‘agonistic’ 1 ,Cdihydro- 
pyridine [3H]Bay K 8644 (83 Ci/mmol) and find 
that it stabilizes only Q 1% of the skeletal muscle 
receptors in the high-affinity state, when compared 
with [3H]PN 200-l 10 or [3H]azidopine. This gives 
further support to the theory that the antagonistic 
nature of 1,Cdihydropyridines is related to their 
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ability to stabilize the channel in the high-affinity 
state for this class of drugs. To explain the dif- 
ference in M, values of the [3H]nimodipine and 
[3H]PN 200-110 labelled channel it was proposed 
that 1,Cdihydropyridines bind directly to a chan- 
nel element (a), which, when binding to fully an- 
tagonistic 1 ,Cdihydropyridines, is coupled to a 
smaller element than when binding a partially 
agonistic 1 ,Cdihydropyridine. From the calculated 
M, values the 1 ,Cdihydropyridine binding element 
(cu) was suggested to have an J4, of ~75000 [6]. 
However, we found that [3H]azidopine, a 1,4-di- 
hydropyridine photoaffinity ligand, was covalently 
incorporated into a band of M, 145000, which is 
twice the size of the proposed 1,Cdihydropyridine 
binding element. Several possibilities may explain 
this apparent paradox. In the target size analysis 
experiments [4,6] an underestimate of the M, by 
100% may have been made. This possibility seems 
remote as the irradiation experiments with the 
Ca”+ channel were performed according to [16] 
where the authors determined the Mr of recombi- 
nant DNA interferon to within 5% of the M, 
known from the amino acid sequence. The pro- 
posed ‘elements’ in our model to explain the target 
size data may be equivalent to what has been 
recently termed ‘radiation sensitive domains’ in the 
case of (Na+ + K+)-ATPase [17]. We cannot ex- 
clude at the present ime that the element (or radia- 
tion sensitive domain) is in fact smaller than the 
receptor carrying peptide chain. Another possibili- 
ty is that [3H]azidopine is photoincorporated into 
a channel protein other than the l,Cdihydropyri- 
dine binding subunit. This suggestion is not unlike- 
ly especially when one calculates the molecular 
dimensions of [3H]azidopine and considers the 
structure-activity relationship of several 1,4-dihy- 
dropyridines (fig.4). The least active 1,6dihydro- 
pyridine in this series is M 5579, with a Ki of 
1.8 PM. At the C3 position of the dihydropyridine 
ring M 5579 has a carboxylic acid residue. Sub- 
stitution with a methyl group (length - 2 A) at this 
position leads to nifedipine with nanomolar Kd 
values in ligand binding experiments. Substitution 
with 2-(ZV-benzyl-N-methylaminoethyl) group 
(length -9.8 A) as in nicardipine results in a 1,4-di- 
hydropyridine with EGO values in functional tests 
of l-7 nM [ 181 and ICSO values in the same range 
in ligand binding experiments [19,20]. For 
[3H]azidopine the addition of a bulky 4-(azido- 
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DRUG 
NIFEDIPINE 
M 5579 
NICARDIPINE 
IODIPINE 
AZIDOPINE 
PN 200 -110 
VO 2605 
Rl R2 
- CH, - CHJ 
NO, 
-l-l -CH, 
Q 
0 
-NO, 
-(CH,J2N<;; 0 
-0 
2 
9 
I 
-(CH212 NC-(CH,), 
n 0 
0 OH 
0 
-(CH,),aC 0 
u 
N, 
/CH, 
-CH 
‘Cl+, 
/CH, 
-CH 
‘CH, 
-C& 
-C,H, 
-C& 
-CH, 
-CH, 
4 14 
1860 18 
7 18 
0.4 18 
0.4 
1.5 14 
320 18 
Fig.4. Structures of 1 ,Cdihydropyridines. Structural formulas and potencies of 1 ,Cdihydropyridines in binding to 
skeletal muscle Ca*+ channels in membrane fragments. Dreiding scale models were made, and measured to determine 
approximate molecule dimensions. For nifedipine the crystal structure is known [22]. For the other 1,4-dihydropyridines 
the molecules were constructed with extended chain forms at the C3 and CS ester substituents of the pyridine ring. The 
molecules were then measured across the C3, C5 axis of the pyridine ring. Total width of the molecules and lengths 
of RI (in A): nifedipine, 10.5, 2; M 5579, 10.1, 1.3; nicardipine, 18, 9.8; iodipine, 23.5, 13,2; azidopine, 22, 11.8; PN 
200-110 and Vo 2605, 12.2, 3.3. 
KD (nM) Ref. 
phenyl)oxoaminoethyl group (length - 11.8 A) at 
the C3 position of the dihydropyridine ring results 
in a ligand with a Kd value in the picomolar range. 
Even addition of a 2-[ I-(3-iodo-4-hydroxyphenyl)- 
3-oxopropyllaminoethyl group does not signifi- 
cantly alter ligand affinity. However, introduction 
of a single Br atom at the para position of the 
4-phenyl ring causes a 200-fold 10~s in PN 200-l 10 
affinity [19]. Substitutions at the para position of 
the 4-phenyl ring residue are known to be highly 
detrimental to 1 ,Cdihydropyridine Ca2+ channel 
blocking potency [21,22]. Thus, substituents at the 
117 
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C3 ester group of the pyridine ring may not be in 
close contact with the surface of the l,Cdihydro- 
pyridine binding protein of the channel because of 
the wide range of potentially sterically hindering 
substituents which are compatible with high-af- 
finity binding. 
A spherical protein of M, 75000 would have a 
radius of -29 A. This is close to the total length of 
[3H]azidopine (-22 A). When the arylazido group 
is activated with ultraviolet light and forms active 
nitrene radicals, this reactive center is -12 A from 
the 1,6dihydropyridine ring, and could possibly 
become incorporated into a closely neighboring 
channel protein. The development of 1,6dihydro- 
pyridines with photoactivatable groups on the 
pyridine nucleus will allow this hypothesis to be ex- 
amined experimentally. A potential 1,4-dihydro- 
pyridine affinity ligand with an isothiocyanate 
group at the ortho position of the 4-phenyl ring has 
been reported to be incorporated into a protein of 
M, 45000 in guinea-pig heart and ileum mem- 
branes using 50 mM Tris buffer [23]. However, 
only PMSF was used to block proteolysis, the 
‘specifically’ incorporated radioactivity was very 
low (peak radioactivity -160 cpm) and no 
fluorograph was shown. So far we have not suc- 
ceeded in covalently incorporating this 1 ,4-[3H]di- 
hydropyridine into guinea-pig skeletal muscle or 
heart membranes specifically even in amine-free 
buffers. Obviously further characterisation and 
purification of the channel components are re- 
quired to resolve these discrepancies. The develop- 
ment of photoaffinity labels for the other drug 
receptor sites of the channel may help to answer 
the questions which are raised by the apparently 
divergent results obtained by target size analysis 
and covalent labelling with [3H]azidopine. 
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